LBA designation will only be given to impactful prospective studies or original research that will change clinical practice and whose data are not available at the time of regular abstract submission due to study events and/or timelines. LBA designation is not a means for extending the regular abs...
"This is a culmination of 15 years of work. My lab was the first to produce natural killer cells from human pluripotent stem cells. Together with Fate Therapeutics, we've been able to show in preclinical research that this new strategy to produce pluripotent stem cell-derived natural killer c...
surgeon, researcher, allied health professional or a student in the field, you can join us to make the connections that will boost your career, see what’s new in gynecologic oncology science and research,
Decades of research have mapped out the basic mechanics of the Hippo pathway. The paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), as the central transcription control module of the Hippo pathway, have long been implicated in the progression of...
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK Kevin J Harrington University of California San Diego Moores Cancer Center, La Jolla, CA, USA Ezra EW Cohen Corresponding author Correspondence to Barbara Burtness. Additional information Competing interests The LUX-Head & ...
https://clinicaltrials.gov/ct2/show/NCT03682289 (2018). The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012). The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature ...
Lin Y, Gerson S: Clinical trials using LB-P140K-MGMT for gliomas. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 379-391. 3 Google Scholar Maier P, Herskind C, Fleckenstein K, Spier I, Laufs S, Zeller WJ, Fruehauf S, Wenz F: MDR...
The study, noted the authors, also raised a caution regarding immunotherapy research of subcutaneous tumor model. "This model was used in the pioneering work for cancer immunotherapy," said Feng, "and it remains the most frequently used animal tumor model in thecancerimmunology. However, our stud...
Astra Zeneca, Pfizer, Astellas and Sanofi Genzyme; and research funding from Janssen, Abbvie Stemcentryx, Eli Lilly, Millenium and Astellas. J.V. is employed by the Prostate Cancer Clinical Trials Consortium. H.R.S., J.W.S. and A.K.M. are employed by the Prostate Cancer Foundation. ...
Research into KRAS-driven tumors and analytical chemistry have borne a new class of selective small molecules against the KRAS G12C isoform. Phase II data for sotorasib (AMG510) has demonstrated a 37.1% overall response rate (ORR). Adagrasib (MRTX849) has demonstrated a 45% ORR in an ...